An observational study in Idiopathic Pulmonary Fibrosis, sponsored by Boehringer Ingelheim. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-01.
Sponsored by Boehringer Ingelheim · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim — 1 open to participants now, 3 under way, 1 of them phase 3. Idiopathic Pulmonary Fibrosis · Boehringer Ingelheim.
Among the 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim, this one is the 12th largest by enrollment of the 16 observational ones that give a count, is one of 4 that started in 2017, is one of 16 observational ones, and was the 14th registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →1 of the 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim is open now, in 9 countries. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in United States, Belgium, Finland and 6 more countries
Ages 40+
By country, each count listing its studies:
Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 172 is above the median of 152 across 165 observational studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 109 across the 18 interventional studies, 212 across the 16 observational. Of the 31 that completed or were terminated, 26 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
2 of the studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06238622Phase 3Boehringer IngelheimA Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast | 2027-04-28 |
| NCT07036523Boehringer IngelheimA Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment | 2027-03-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The present study has been designed to characterize IPF patients treated with nintedanib (OFEV®), at time of treatment initiation, with respect to their clinical profile based on real-world data from January 2016 in Spanish Pulmonology Services.
Approximately 175 IPF patients from 35 Pulmonology Services in Spain are planned to be included in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: L - Antineoplastic and immunomodulating agents
Drug: L01 - Antineoplastic agents
Drug: L01X - Other antineoplastic agents
Drug: L01XE - Protein kinase inhibitors
Drug: L01XE31 - Nintedanib
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01X - Other antineoplastic agents
L01XE - Protein kinase inhibitors
L01XE31 - Nintedanib
Also known as: OVEF
Percentage of Patients Across Different Lung Function Categories (% FVC (Forced Vital Capacity))
The distribution of patients across different lung function categories (% FVC serving as surrogate markers for IPF severity) of IPF patients treated with nintedanib (OFEV®) in routine clinical practice, at the time of treatment initiation.
Time frame: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.
Percentage of Patients Across Different Lung Function Categories (% DLCO (Diffusing Capacity of the Lungs for Carbon Monoxide))
The distribution of patients across different lung function categories (% DLCO serving as surrogate markers for IPF severity) of IPF patients treated with nintedanib (OFEV®) in routine clinical practice, at the time of treatment initiation.
Time frame: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.
The Demographic Baseline Characteristics - Age at the Time of Treatment Initiation
The age of IPF patients at the time of treatment initiation with nintedanib (OFEV®) is presented.
Time frame: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.
The Clinical Baseline Characteristics - Duration of the Disease
Duration of the disease of IPF patients, calculated as the time elapsed from the date of diagnosis until the start date of treatment with OFEV® (years).
Time frame: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.
The Clinical Baseline Characteristics - Percentage of Patients With Emphysema
The percentage of patients with emphysema at the start of treatment with nintedanib (OFEV®) is presented.
Time frame: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.
The Clinical Baseline Characteristics - Percentage of Patients With Usual Interstitial Pneumonia (UIP) Histopathological Pattern
The usual interstitial pneumonia (UIP) histopathological pattern of IPF patients at the time of treatment initiation with nintedanib (OFEV®) is presented.
Time frame: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.
The Clinical Baseline Characteristics - Percentage of Patients With UIP Radiological Pattern
The UIP radiological pattern of IPF patients at the time of treatment initiation with nintedanib (OFEV®) is presented.
Time frame: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.
The Clinical Baseline Characteristics - Percentage of Patients With the Initial Dose of OFEV®
The percentage of patients initiated OFEV® dose of 150 milligram (mg)/ 12 hours (h) and 100 mg/12 h is presented.
Time frame: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.
The Demographic Baseline Characteristics - Weight at the Start of Nintedanib Therapy
The weight of IPF patients at the start of treatment with nintedanib (OFEV®) is presented.
Time frame: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.
The Demographic Baseline Characteristics - Height at the Start of Nintedanib Therapy
The height of IPF patients at the start of treatment with nintedanib (OFEV®) is presented.
Time frame: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.
The Demographic Baseline Characteristics - Body Mass Index (BMI) at the Start of Nintedanib Therapy
The body mass index (BMI) of IPF patients at the start of treatment with nintedanib (OFEV®) is presented.
Time frame: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.
The Demographic Baseline Characteristics - 6-minute Walk Test
The 6-minute walk test of IPF patients at the time of treatment initiation with nintedanib (OFEV®) is presented.
Time frame: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.
The Demographic Baseline Characteristics - Percentage of Patients With Smoking Habit
The percentage of patients with smoking habit at the start of treatment with nintedanib (OFEV®) is presented.
Time frame: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.
The Clinical Baseline Characteristics - Percentage of Patients With Dyspnoea
The percentage of patients with dyspnoea at the start of treatment with nintedanib (OFEV®) is presented.
Time frame: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.
The Clinical Baseline Characteristics - Percentage of Patients With Exacerbations
The percentage of patients with exacerbations of IPF in the year prior to initiating treatment is presented.
Time frame: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.
The Clinical Baseline Characteristics - Percentage of Patients With Concomitant Treatments
The percentage of patients taking any concomitant medication at the start of nintedanib therapy is presented.
Time frame: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.
Percentage of Patients With Prevalence of Comorbidity (Concomitant Diseases) at the Time of Treatment Initiation.
The percentage of patients with comorbidity (concomitant diseases) at the start of treatment with nintedanib (OFEV®) is presented.
Time frame: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.
Percentage of Patients With Other Concomitant Diseases at the Time of Treatment Initiation.
The percentage of patients with other concomitant diseases at the start of treatment with nintedanib (OFEV®) is presented.
Time frame: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.
Percentage of Patients Distributed Across Different Lung Function Categories Based on the Reimbursement Threshold (%FVC)
The distribution of patients across different lung function categories based on the reimbursement threshold (FVC \>80%, 50-80%, and \<50%).
Time frame: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.
Non-interventional study based on medical charts was conducted in approximately 35 pulmonology services in Spanish hospitals. Idiopathic pulmonary fibrosis (IPF) patients were characterized at the time of nintedanib initiation. Analysis of this report was performed using the data collected in the database from 21October2017 up to 31January2018.
| Milestone | Total Patients With IPF |
|---|---|
| Started | 172 |
| Completed | 172 |
| Not completed | 0 |
The distribution of patients across different lung function categories (% FVC serving as surrogate markers for IPF severity) of IPF patients treated with nintedanib (OFEV®) in routine clinical practice, at the time of treatment initiation.
| Percentage of Patients (%) | Total Patients With IPF |
|---|---|
| Mild IPF: FVC ≥ 70% | 57.0 |
| Moderate IPF: FVC between 50% and 69% | 38.4 |
| Severe IPF: FVC < 50% | 4.7 |
The distribution of patients across different lung function categories (% DLCO serving as surrogate markers for IPF severity) of IPF patients treated with nintedanib (OFEV®) in routine clinical practice, at the time of treatment initiation.
| Percentage of Patients (%) | Total Patients With IPF |
|---|---|
| Mild IPF: DLCO ≥ 50% | 42.5 |
| Moderate IPF: DLCO between 35% and 49% | 35.3 |
| Severe IPF: DLCO < 35% | 22.2 |
The age of IPF patients at the time of treatment initiation with nintedanib (OFEV®) is presented.
| Years | Total Patients With IPF |
|---|---|
| The Demographic Baseline Characteristics - Age at the Time of Treatment Initiation | 70.1 ± 8.1 |
Duration of the disease of IPF patients, calculated as the time elapsed from the date of diagnosis until the start date of treatment with OFEV® (years).
| Years | Total Patients With IPF |
|---|---|
| The Clinical Baseline Characteristics - Duration of the Disease | 1.5 ± 3.8 |
The percentage of patients with emphysema at the start of treatment with nintedanib (OFEV®) is presented.
| Percentages of Patients | Total Patients With IPF |
|---|---|
| No | 84.3 |
| Yes | 15.7 |
The usual interstitial pneumonia (UIP) histopathological pattern of IPF patients at the time of treatment initiation with nintedanib (OFEV®) is presented.
| Percentages of Patients | Total Patients With IPF |
|---|---|
| No | 13.4 |
| Yes | 30.8 |
| No data | 55.8 |
The UIP radiological pattern of IPF patients at the time of treatment initiation with nintedanib (OFEV®) is presented.
| Percentages of Patients | Total Patients With IPF |
|---|---|
| No | 9.9 |
| Yes | 89.0 |
| No data | 1.2 |
The percentage of patients initiated OFEV® dose of 150 milligram (mg)/ 12 hours (h) and 100 mg/12 h is presented.
| Percentages of Patients | Total Patients With IPF |
|---|---|
| 150 mg/12 h | 88.4 |
| 100 mg/12 h | 11.0 |
| No data | 0.6 |
The weight of IPF patients at the start of treatment with nintedanib (OFEV®) is presented.
| Kilogram (Kg) | Total Patients With IPF |
|---|---|
| The Demographic Baseline Characteristics - Weight at the Start of Nintedanib Therapy | 77.1 ± 13.2 |
The height of IPF patients at the start of treatment with nintedanib (OFEV®) is presented.
| Centimeters (cm) | Total Patients With IPF |
|---|---|
| The Demographic Baseline Characteristics - Height at the Start of Nintedanib Therapy | 164.5 ± 8.9 |
The body mass index (BMI) of IPF patients at the start of treatment with nintedanib (OFEV®) is presented.
| Kilogram/ meter^2 (kg/m^2) | Total Patients With IPF |
|---|---|
| The Demographic Baseline Characteristics - Body Mass Index (BMI) at the Start of Nintedanib Therapy | 28.4 ± 3.8 |
The 6-minute walk test of IPF patients at the time of treatment initiation with nintedanib (OFEV®) is presented.
| Meter (m) | Total Patients With IPF |
|---|---|
| The Demographic Baseline Characteristics - 6-minute Walk Test | 421.7 ± 118.6 |
The percentage of patients with smoking habit at the start of treatment with nintedanib (OFEV®) is presented.
| Percentage of Participants | Total Patients With IPF |
|---|---|
| Never smoker | 33.1 |
| Former smoker | 64.0 |
| Active smoker | 2.9 |
The percentage of patients with dyspnoea at the start of treatment with nintedanib (OFEV®) is presented.
| Percentages of Partients | Total Patients With IPF |
|---|---|
| No | 5.2 |
| Yes | 93.0 |
| No data | 1.7 |
The percentage of patients with exacerbations of IPF in the year prior to initiating treatment is presented.
| Percentages of patients | Total Patients With IPF |
|---|---|
| No | 84.9 |
| Yes | 11.6 |
| No data | 3.5 |
The percentage of patients taking any concomitant medication at the start of nintedanib therapy is presented.
| Percentages of Patients | Total Patients With IPF |
|---|---|
| No | 20.3 |
| Yes | 79.7 |
The percentage of patients with comorbidity (concomitant diseases) at the start of treatment with nintedanib (OFEV®) is presented.
| Percentages of Patients | Total Patients With IPF |
|---|---|
| Hypertension | 45.9 |
| Dyslipidaemia | 42.4 |
| Gastroesophageal reflux | 25.6 |
| Diabetes mellitus | 19.8 |
| Emphysema | 15.7 |
| Cardiovascular disease | 15.7 |
| Obstructive sleep apnoea | 11.6 |
| Pulmonary hypertension | 5.8 |
| Lung cancer | 1.7 |
| Pulmonary infection | 1.2 |
The percentage of patients with other concomitant diseases at the start of treatment with nintedanib (OFEV®) is presented.
| Percentages of Patients | Total Patients With IPF |
|---|---|
| Percentage of Patients With Other Concomitant Diseases at the Time of Treatment Initiation. | 41.9 |
The distribution of patients across different lung function categories based on the reimbursement threshold (FVC \>80%, 50-80%, and \<50%).
| Percentages of Patients | Total Patients With IPF |
|---|---|
| Mild IPF: FVC > 80% | 33.1 (26.3 to 40.8) |
| Moderate IPF: FVC between 50% and 80% | 62.2 (54.5 to 69.4) |
| Severe IPF: FVC < 50% | 4.7 (2.2 to 9.3) |
Collected over From start of drug administration (01Jan16) until final data set (07Jun18). i.e. Up to 889 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Total Patients With IPF | 10/172 (5.8%) | 13/172 (7.6%) | 38/172 (22.1%) |
| Event | Total Patients With IPF |
|---|---|
| Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 3/172 |
| DeathGeneral disorders | 2/172 |
| Acute coronary syndromeCardiac disorders | 1/172 |
| Cardiac failure congestiveCardiac disorders | 1/172 |
| DiarrhoeaGastrointestinal disorders | 1/172 |
| HepatotoxicityHepatobiliary disorders | 1/172 |
| Pneumonia pneumococcalInfections and infestations | 1/172 |
| Weight decreasedInvestigations | 1/172 |
| Transitional cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/172 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 1/172 |
| Event | Total Patients With IPF |
|---|---|
| DiarrhoeaGastrointestinal disorders | 38/172 |
All enrolled patients who met the selection criteria.
| Age, Continuous(Years) | Total Patients With IPF |
|---|---|
| Mean | 71.0 ± 8.1 |
| Sex/Gender, Customized(Particpants) | Total Patients With IPF |
|---|---|
| Male | 131 |
| Female | 40 |
| No data | 1 |
| Ethnicity (NIH/OMB)(Participants) | Total Patients With IPF |
|---|---|
| Hispanic or Latino | — |
| Not Hispanic or Latino | — |
| Unknown or Not Reported | — |
| Race/Ethnicity, Customized(Participants) | Total Patients With IPF |
|---|---|
| Caucasian | 170 |
| Asiatic | 1 |
| Arab | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Oct 2017 to primary completion in Jun 2018, 7 months.
Results were first posted in Aug 2019, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Idiopathic Pulmonary Fibrosis →